This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/525459-moderna-vaccine-global-supply-dose/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 1 | Version 2 |
|---|---|
| Moderna plans to offer Covid-19 vaccine with range of dosages after new deal with Swiss drugmaker Lonza | Moderna plans to offer Covid-19 vaccine with range of dosages after new deal with Swiss drugmaker Lonza |
| (about 2 months later) | |
| Moderna has said it will likely offer a range of vaccine dose levels in 2022 after a successful trial of a half-dose booster shot and a deal with drugmaker Lonza to provide ingredients for 300 million 50 microgram doses each year. | Moderna has said it will likely offer a range of vaccine dose levels in 2022 after a successful trial of a half-dose booster shot and a deal with drugmaker Lonza to provide ingredients for 300 million 50 microgram doses each year. |
| “We’re assuming that as of 2022, we are going to have a mix of dose levels on the market,” a spokeswoman for Moderna told Reuters on Wednesday, following the announcement that Swiss firm Lonza could provide enough ingredients for 300 million doses of Moderna’s Covid-19 jab at a reduced dosage. | “We’re assuming that as of 2022, we are going to have a mix of dose levels on the market,” a spokeswoman for Moderna told Reuters on Wednesday, following the announcement that Swiss firm Lonza could provide enough ingredients for 300 million doses of Moderna’s Covid-19 jab at a reduced dosage. |
| Moderna’s vaccine has been administered in a 100-microgram dose to date but following positive trial data, the company hopes to gain approval for a 50-microgram dose. | Moderna’s vaccine has been administered in a 100-microgram dose to date but following positive trial data, the company hopes to gain approval for a 50-microgram dose. |
| Lonza’s Geleen site in the Netherlands will contribute to the supply of an additional 300 million doses of Moderna’s updated booster variant vaccine candidate per year at a 50-microgram dose. | Lonza’s Geleen site in the Netherlands will contribute to the supply of an additional 300 million doses of Moderna’s updated booster variant vaccine candidate per year at a 50-microgram dose. |
| Combined with a previous deal with ROVI in Granada, Spain, Moderna expects to supply the equivalent of 600 million 50-microgram doses each year from production sites within the EU. | Combined with a previous deal with ROVI in Granada, Spain, Moderna expects to supply the equivalent of 600 million 50-microgram doses each year from production sites within the EU. |
| The company has previously stated that a 50-microgram booster shot was sufficient to provide added immune response, even against the variants originating in Brazil and South Africa. | The company has previously stated that a 50-microgram booster shot was sufficient to provide added immune response, even against the variants originating in Brazil and South Africa. |
| In April, Moderna President Stephen Hoge said the company sees huge demand for Covid-19 vaccines in 2022, which underpinned its decision to produce up to 3 billion doses next year. | In April, Moderna President Stephen Hoge said the company sees huge demand for Covid-19 vaccines in 2022, which underpinned its decision to produce up to 3 billion doses next year. |
| A week previous, the company’s CEO, Stephane Bancel, predicted that there would actually be too much supply globally in 2022, noting: “Well, if anything that is a good problem to have in terms of dealing with the pandemic but it’s not a nice problem to have if you’re the one manufacturing the vaccine I guess.” | A week previous, the company’s CEO, Stephane Bancel, predicted that there would actually be too much supply globally in 2022, noting: “Well, if anything that is a good problem to have in terms of dealing with the pandemic but it’s not a nice problem to have if you’re the one manufacturing the vaccine I guess.” |
| If you like this story, share it with a friend! | If you like this story, share it with a friend! |